Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05204121
Other study ID # HIV-VM1500-09
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date December 18, 2018
Est. completion date April 2, 2019

Study information

Verified date January 2022
Source Viriom
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A randomized once weekly dose for 8 weeks, study in Healthy HIV-Uninfected Volunteers. Each of 3 parallel groups (40 mg, 80 mg and 160mg) enrolls 12 subjects.


Description:

The study aims to assess safety, tolerability and PK of once weekly administration of Elpida in different doses.


Recruitment information / eligibility

Status Completed
Enrollment 36
Est. completion date April 2, 2019
Est. primary completion date April 2, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: 1. Men and women aged 18 to 55 years; 2. Verified diagnosis "healthy" according to medical history, physical examination, assessment of vital signs, electrocardiography (ECG), investigations performed in the last 14 days prior to the first administration of IP; 3. Body mass index (BMI) from 18.5 kg/m2 to 30 kg/m2 (inclusive), bodyweight of 50 kg or higher; 4. Negative result of alcohol and drug tests; 5. Women must be in postmenopause for at least 2 years, be surgically sterile or use two reliable methods of contraception from the day of screening and until 3 months after the last dose; 6. Men must use two reliable methods of contraception* from the day of screening and until 3 months after the last dose; 7. Ability to understand the meaning of the study and any risks associated with participation. Ability to interact with the investigator, participate and comply with the requirements of the study throughout its duration; 8. Willingness to sign written consent to participate in the study after reading Informed Consent Form with the opportunity to discuss any questions with the investigator (and/or his/her representative). Exclusion Criteria: 1. Participation in more than one group of investigational therapy; 2. Past or present diseases of the cardiovascular, bronchopulmonary, neuroendocrine, musculoskeletal systems, as well as diseases of the gastrointestinal tract, liver, kidneys, blood that may interfere with achievement of objectives of this study or affect the safety of a volunteer; 3. The values of laboratory and instrumental parameters, beyond the limit of normal ; 4. Past or present diseases or pathologies, including surgical interventions in the gastrointestinal tract that, in the opinion of the Investigator, may affect the absorption, distribution, metabolism or excretion of the investigational product; 5. A systolic pressure of less than 90 mm Hg or greater than 130 mm Hg; diastolic pressure of less than 60 mm Hg or greater than 85 mm Hg; pulse rate of less than 60 bpm or greater than 90 bpm (at screening); 6. Deviations detected during 12-lead ECG, or QT/QTc interval > 450 milliseconds (ms) for men and > 470 ms for women; 7. Administration of any drugs n, including over-the-counter products, herbal, food, dietary or vitamin supplements 14 days before the first administration of the investigational product; 8. Administration of the following drugs for 28 days prior to screening: corticosteroids (any route of administration); IP that inhibit the activity of cytochrome P450 3A4 (CYP3A4; for example, ritonavir and other drugs for human immunodeficiency virus (HIV), ketoconazole, itraconazole, or similar azole antifungals and macrolide antibiotics such as erythromycin), or the use of any drugs with a significant likely effect on functions of organs (for example, barbiturates, omeprazole, cimetidine); 9. Hepatitis B (HBsAg), antibodies to hepatitis C and HIV, a positive test for syphilis; 10. Positive pregnancy test (for women); 11. Acute infectious diseases less than 4 weeks before screening; 12. Unstable sleeping hours (for example, night shift, sleep disorders, insomnia, jet lag, etc.); 13. Signs of alcohol or drug addiction; intake of alcohol or drugs 4 days prior to screening and during the study; smoking cigarettes 3 months prior to screening and during the study; positive drug and/or alcohol test; 14. Complicated allergic history (including intolerance to medication, including hypersensitivity to the active substance/excipients of the investigational drug) and food allergy; 15. Blood/plasma donation (450 mL of blood or plasma or more) less than 2 months before screening; 16. Participation in another clinical study or administration of any investigational products less than 3 months before screening; 17. Any other concomitant medical or significant mental conditions that render a volunteer unsuitable for participation in the clinical study; 18. A volunteer who is considered for enrollment in the study is an employee of the study site or company of the Sponsor or a member of an employee's family

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Elpida
elsulfavirine, capsules

Locations

Country Name City State
Russian Federation Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University) Moscow

Sponsors (1)

Lead Sponsor Collaborator
Viriom

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of AEs and SAEs Incidence of AEs and SAEs 77 days
Secondary elsulfavirine plasma concentration elsulfavirine plasma concentration 77 days
Secondary VM1500A plasma concentration active metabolite plasma concentration 77 days
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT06072443 - AURORA Study-A Transformative Approach to Support PrEP Medication Persistence
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV